(KNDL) - Kendle International, Inc - The company has exceeded earnings estimates in seven out of the past eight quarters

Kendle has exceeded earnings estimates in seven out of the past eight quarters, with five of those positive surprises exceeding 10%. Year-over-year growth exploded over that time period as well. Over the past 60 days, this year's estimates have increased 4.7% to $1.33 per share, while next year's have risen 4.2% to $1.75 per share. Full Analysis Kendle International, Inc. (KNDL), a clinical research organization, provides various Phase I-IV clinical development services to the biopharmaceutical industry worldwide. Its clinical research services include clinical trial management, clinical data management, statistical analysis, medical writing, regulatory consulting and organizational meeting management, and publications services on a contract basis. The company said this week its third-quarter profit rose 18%, lifted by improved revenue. Net income rose to nearly $4 million, or 27 cents per share, from $3.4 million, or 24 cents per share. Total revenue rose 50% to $96.7 million. Net services revenue gained 46% to $75.2 million, of which 24% reflects organic growth and the remainder reflects the August purchase of the Phase II-IV clinical services business of Charles River Laboratories International "Kendle continues to focus first and foremost on meeting the global clinical development needs of our customers," said Candace Kendle, PharmD, Chairman and Chief Executive Officer. "Our enhanced position in the marketplace and expanded therapeutic expertise are already having a strong impact on our results. During the quarter we delivered significant growth in backlog and new business awards, further strengthening and diversifying our customer base and demonstrating the confidence our customers have in Kendle as a global provider." The company has exceeded earnings estimates in seven out of the past eight quarters, with five of those positive surprises exceeding 10%. Year-over-year growth exploded over that time period as well. Over the past 60 days, this year's estimates have increased 4.7% to $1.33 per share, while next year's have risen 4.2% to $1.75 per share. The stock is currently trading at 19.4x next year's estimate of $1.75 per share, well below the company's projected long-term growth rate of 42%, giving the stock a PEG ratio of 0.46. Content Courtesy: Zacks Investment Research #1 Ranked Stocks Highlight Archive To truly take advantage of the Zacks Rank, you need to first understand how it works. That is why we created the free special report: Zacks Rank Guide: Harnessing the Power of Earnings Estimate Revisions. | Blog Home| VitalStocks Home